FHTX vs KURA
FHTX: Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal gene expression. KURA: Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
Side-by-side fundamentals
| Metric | FHTX | KURA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.21 | $10.54 | |
| Market cap as of 2026-07-23 | $306M | $944M | |
| PEG as of 2026-07-23 | n/a | -0.05 | |
| Net margin as of 2026-07-23 | -266.9% | -411.2% | FHTX higher |
| Gross margin as of 2026-07-23 | n/a | +99.9% | |
| Operating margin as of 2026-07-23 | -301.3% | -443.5% | FHTX higher |
| ROE as of 2026-07-23 | -301.6% | -141.9% | KURA higher |
| ROA as of 2026-07-23 | -35.4% | -43.3% | FHTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.09 | FHTX lower |
| Revenue growth (YoY) as of 2026-07-23 | +20.1% | +29.5% | KURA higher |
| Revenue CAGR (3y) SEC XBRL | +17.1% | n/a | |
| Beta as of 2026-07-23 | 2.80 | 0.37 | |
| 1-year return as of 2026-07-22 close | -15.4% | +58.0% | KURA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.